Each mL contains: Citicoline (as sodium) 250 mg.
Preservative: Methyl paraben BP: 0.18% w/v.
Propyl paraben B.P: 0.02% w/v.
Water for injection BP q.s.
Pharmacology: Pharmacodynamics: Citicoline activates the bio-synthesis of structural phospholipids in the neuronal membrane, increases cerebral metabolism and increases the level of various neurotransmitters, including acetylcholine and dopamine. Citicoline has shown neuro-protective effects in situations of hypoxia and ischaemia, as well as improved learning and memory performance in animal models for the brain aging. Furthermore, it has been demonstrated that Citicoline restores the activity of mitochondrial ATPase and of membranal Na+/K + ATPase, inhibits the activation of phospholipase A2 and accelerates the re-absorption of cerebral edema in various experimental models.
Pharmacokinetics: When administered orally, it is absorbed almost completely and its bioavailability is approximately the same when administered intravenously. Once absorbed, the cytidine and choline disperse widely throughout the body, cross the blood-brain barrier, and reach the central nervous system (CNS), where they are incorporated into the phospholipids fraction of the cellular membrane and microsomes.
The concept, that the administration of exogenous Citicoline can augment the synthesis of neural membrane phospholipids is attractive, because accelerated replacement or repair plays a critical role in maintaining the healthy function of numerous physiological processes. It has shown the therapeutic efficacy in a variety of diseases in which membrane disorder, dysfunction or degeneration result in cellular and tissue ischaemia and necrosis.
For the treatment of cerebrovascular disorders (including ischaemic stroke), Parkinsonism and head injury
125 mg/mL Solution for Injection once or twice daily, 250 mg/mL once a day only.
Or, as prescribed by a physician.
Hypersensitivity to Citicoline and its components.
Patients with a history of convulsion, suicidal tendencies.
Hepatic or renal impairment.
Must not be administered in conjunction, with medications containing centrophenoxine.
May impair ability to drive or operate machinery.
There is inadequate evidence of safe use of Citicoline in human pregnancy. Citicoline should be used in pregnancy and lactation only if the potential benefits justify the potential risks.
Occasionally Citicoline may exert a stimulating action of the parasympathetic, as well as discreet and fleeting hypotensive effect.
These are some following adverse effects that occur with Citicoline: Rash; insomnia; headache; dizziness; seizure; nausea; anorexia; abnormal liver function from laboratory check; diplopia; malaise.
Citicoline potentiates the effects of L-dopa.
Store at temperatures not exceeding 30°C.
Shelf-life: 24 months.
N06BX06 - citicoline ; Belongs to the class of other psychostimulants and nootropics.
Cevor I.V soln for inj 250 mg/mL
4 mL x 5 × 1's
Sign Out
